

Doctor

José Luis Salazar

Jefe de División de Nuevas Creaciones ((

SUPERINTENDENCIA DE INDUSTRIA Y CO.

E. S. D.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 08-052929- -00006-0000

Fecha: 2012-09-21 16:19:21
Tra. 11 PATENTEIYII
Act. 523 RESPUESTA

Dep. 2020 DIR.NUEVASCR
Eve: 378 FASENACIONALI
Folios: 91

Referencia: Expediente No. 08.052.929

Solicitud de Patente de Invención titulada: "Compuestos de benzamidilo como inhibidores de la proteína de transferencia de éster de colesterilo"

Solicitante: Bristol Myers Squibb Company

RESPUESTA AL AUTO NOTIFICADO POR FIJACIÓN EN LISTA No.286
DEL 30 DE MAYO DE 2012, OFICIO NO. 08779 (EXAMEN DE FONDO)

ÁLVARO CORREA ORDÓÑEZ, mayor de edad y vecino de Bogotá D.C., identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, doy respuesta al auto emanado por ese Despacho dentro del término de prórroga solicitado el 30 de Agosto de 2012 con número de radicación 08-052929-00005-0000:

1. Excepciones a la patentabilidad

Su Despacho establece que las reivindicaciones 15 a 19 se relacionan con un método de tratamiento, materia no patentable en Colombia.

Para atender a esta observación informamos a su Despacho que dichas reivindicaciones se cancelaron del pliego reivindicatorio.

2. Título de la invención

El examinador sugiere que se corrija el título de la invención ya que se considera que el término "Compuestos homo y heterocíclicos adecuados" no es claro.

Con el propósito de atender a la anterior observación, me permito presentar un nuevo título como sigue:

"Compuestos de benzamídeos como inhibidores de la proteína de transferencia de éster de colesterol"

3. Claridad de las reivindicaciones

Modificación a una solicitud en trámite:

De conformidad con el artículo 34 de la Decisión 486 que permite al solicitante efectuar modificaciones a su solicitud en cualquier momento del trámite sin que se presente ampliación de la invención originalmente presentada, y con el propósito de atender a las observaciones del examinador, me permito presentar un nuevo pliego reivindicatorio que comprende 8 reivindicaciones.

Las modificaciones efectuadas se encuentran totalmente sustentadas en la memoria descriptiva originalmente presentada, ejemplos y reivindicaciones originales.

El examinador podrá notar que el término "opcionalmente" se canceló del pliego reivindicatorio y la reivindicación 14 que ahora con la nueva numeración corresponde a la 8 se corrigió de tal forma que incluye los agentes terapéuticos adicionales específicos y las reivindicaciones 20-23 se cancelaron.

Con relación a la observación del examinador en cuanto a que las reivindicaciones 1 y 3 a 11 carecen de soporte porque los radicales A, B, C y R1 difieren a los mencionados en el capítulo descriptivo. Informamos a su Despacho que dichas reivindicaciones han sido modificadas de tal forma que el alcance de los sustituyentes A, B, C y R1 se definieron como se establecen en las reivindicaciones originales 10 y 11.

Se informa a su Despacho que el nuevo pliego reivindicatorio se encuentra totalmente sustentado en la memoria descriptiva originalmente presentada.

4. Claridad de la descripción

Su Despacho establece que la descripción no es clara porque la información que contiene no permite que la persona del oficio normalmente versada en la materia pueda comprender el problema técnico y la solución aportada por la invención puesto que:

4.1 La descripción tiene errores de tipografía y de redacción. Se sugiere corregir los errores de escritura y de traducción del capítulo descriptivo para darle claridad.

De acuerdo con la cita que tuvimos en su Despacho el día 22 de Agosto de 2012 con la examinadora a cargo del asunto y de conformidad con el email recibido el 5 de septiembre de 2012 enunciando los folios en los cuales hay errores de digitación, me permito presentar un nuevo texto en un CD el cual corresponde también a la descripción de la solicitud divisional en donde se cambió el término "diaestereómeros" por "diastereoisómeros", se corrigió el error tipográfico "interiomediarios" por "intermediarios" se cambió el término "substituyentes" por "sustituyentes", el término "mezcla de diaestereómeros" se cambió por "mezcla de diastereoisómeros" y el término "mezcla diaestereomérica" se cambió por "mezcla diastereoisomérica".

4.2 Se relacionan las marcas como Adalat y Calan entre otras, en el folio 1137 o página 301. El examinador sugiere que se definan los nombres genéricos.

Al respecto, mi representada afirma que una persona del oficio normalmente versada en la materia entendería las marcas a las que se hace referencia en la descripción. Sin embargo, se aclara que las marcas Adalat y Calan se refieren a "nifedipina" y "verapamil" respectivamente.

En conexión con lo anterior, me permito dirigir la atención del señor Examinador a las enseñanzas del Manual Andino de Patentes, el cual recita lo siguiente¹ :

"Las marcas registradas o nombres comerciales definen productos o proceso que puedan cambiar con el paso del tiempo aunque conserven el mismo nombre. Por ello su uso en una reivindicación no está permitido ya que no permite establecer el alcance de la reivindicación".

De lo anterior es claro que en la descripción si se pueden utilizar marcas o nombres comerciales pero no en las reivindicaciones. En el presente caso el pliego reivindicatorio no contiene marcas comerciales.

4.3 Mi representada también afirma que la presente invención proporciona tanto datos cualitativos como cuantitativos que describen suficientemente las propiedades farmacológicas de los compuestos de la presente invención.

En primer lugar, tal como se establece en la descripción, los compuestos de la presente invención demuestran que inhiben la proteína de transferencia de éster de colesterol (CETP) mayor que un 30% a dos diferentes concentraciones de menos de 100 uM, preferiblemente con una potencia menor a 5 uM, más preferiblemente con una potencia menor a 500 nM. Se encontró también que los compuestos de la presente invención inhiben la actividad de la transferencia de éster de colesterol utilizando ensayos *in vitro* que contienen hasta 96% de plasma y para inhibir la actividad de transferencia del éster de colesterol en plasma en animales. Por favor ver la página 256 del texto de la presente solicitud. Así como la descripción originalmente presentada contiene datos con relación a la actividad farmacológica de los compuestos. La descripción tal como se presentó originalmente proporciona ejemplos de ensayos adecuados que una persona medianamente experta en la materia puede utilizar para determinar la capacidad de los compuestos para inhibir CETP. Por último, mi representada respetuosamente afirma que el examinador no ha proporcionado evidencia, tal como arte previo, de que esta área de tecnología es compleja, no predecible, etc, tal que la persona medianamente experta en la materia no sería capaz de llevar a cabo la presente invención. Debido a que mi representada ha

¹ Manual para el examen de solicitudes de patentes de invención en las Oficinas de Propiedad Industrial de los países de la Comunidad Andina, 2004, 4.6.4 Marcas registradas o nombres comerciales.

proporcionado tanto datos cualitativos como cuantitativos que demuestran al experto en la técnica que los compuestos de la presente invención demuestran efectos farmacológicos, y el examinador no proporcionó ninguna evidencia o razones técnicas de lo contrario. Se considera contrario a lo que afirma el examinador que la presente invención soporta suficientemente los compuestos que ahora se reclaman.

4.4 Su Despacho afirma que los términos "ISCO" y "CLEM" de las páginas 449 y 736 son poco reconocidos en el campo técnico y sugiere que se definan correctamente.

Al respecto mi representada menciona que una persona del oficio normalmente versada en la materia entendería lo que la expresión "ISCO" representa. Sin embargo, con el fin de agilizar el trámite la presente invención el término "ISCO" se cambió por isocrática.

Con relación al término CLEM, informamos a su Despacho que por error tipográfico dicho término debió escribirse CL-EM que significa "cromatografía líquida-espectrometría de masa". Al respecto el nuevo texto se presenta con las respectivas correcciones.

5. Unidad de invención:

Su Despacho establece que la solicitud no cumple con el requisito de unidad de invención ya que se refiere a 6 grupos inventivos.

Al respecto informamos a su Despacho que la presente solicitud se definió de forma similar al primer grupo establecido por el examinador.

Por otro lado, se presenta una solicitud divisional de la materia restante de la presente invención.

6. Nivel inventivo


Su Despacho establece que los documentos D1 (WO2005037796) y D2 (US2002177708) afectan el nivel inventivo de las reivindicaciones 1 a 14 de la presente invención.

7. Argumentos en favor del inventivo


El nivel inventivo de una solicitud se encuentra definido en el Artículo 18 de la Decisión 486 y se establece cuando *“si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica”*.

Contrario a lo que plantea el Examinador, el documento del arte previo citado no afecta el nivel inventivo de la presente solicitud por cuanto no es posible derivar la presente invención a partir de las enseñanzas presentadas en los documentos D1 y D2 debido a lo siguiente:


El examinador podrá notar que el documento D1 no revela de ninguna manera los compuestos del pliego reivindicatorio que ahora se presenta. Por ejemplo, D1 revela compuestos en los cuales el sustituyente correspondiente al átomo central de la presente



invención es un heteroátomo de nitrógeno. Por el contrario, los compuestos de las reivindicaciones modificadas requieren que el átomo central sean un grupo metileno



. Adicionalmente, D1 requiere que los compuestos que contienen un nitrógeno



contengan un grupo bicíclico aromático

. Por el contrario,


los compuestos tal como se reclaman en el pliego reivindicatorio modificado no pueden contener un nitrógeno que contenga un grupo bicíclico aromático. En ninguna parte del documento D1 se enseña o se revela que el grupo central pueda ser un grupo metileno o compuestos sin un nitrógeno que contiene un grupo bicíclico aromático.

Adicionalmente, una persona del oficio normalmente versada en la materia no estaría motivada a modificar los compuestos del documento D1 para llegar a los compuestos de la

presente invención debido a la imprevisibilidad en el arte de la química sintética (Por favor, ver el artículo que se adjunta "Side Reactions in Organic Synthesis: A guide to succesful synthesis design", 2005, Wiley-VCH Verlag GmbH & Co., KGaA, Wienheim.

De conformidad con las diferencias arriba citadas se considera que el nuevo pliego reivindicatorio que se presenta es inventivo con relación al documento D1.

Con relación al documento D2, este documento no revela los compuestos del capítulo reivindicatorio modificado de la presente invención. Por ejemplo, el documento D2 revela compuestos en el cual el átomo de nitrógeno correspondiente al átomo de nitrógeno en el -NH(R₁) de la presente invención es requerido que sea di-sustituido



. Por el contrario, los compuestos tal como se reclaman en el capítulo reivindicatorio modificado no pueden tener el átomo de nitrógeno que sea di-sustituido. Por el contrario, se requiere que el átomo de nitrógeno sea mono-sustituido, es decir, que sea sustituido solamente con R₁.

Adicionalmente, D2 no permite un sustituyente correspondiente a R₁ de la presente invención que sea un grupo carbonilo sustituido (-C(=O)). Por el contrario, los compuestos tal como se reclaman en las reivindicaciones modificadas requieren que R₁ sea un grupo carbonilo sustituido (R₁ = -C(=O)R₃). Mi representada respetuosamente afirma que una persona del oficio normalmente versada en la materia no sería motivada a modificar los compuestos del documento D2 para llegar a los compuestos de la presente invención debido a la imprevisibilidad en el arte de la química sintética (Por favor, ver el artículo que se adjunta "Side Reactions in Organic Synthesis: A guide to succesful synthesis design", 2005, Wiley-VCH Verlag GmbH & Co., KGaA, Wienheim.

De conformidad con las diferencias arriba citadas se considera que el nuevo pliego reivindicatorio que se presenta es inventivo con relación al documento D2.


En este orden de ideas, tenemos que la invención propuesta por el solicitante si cumple con los requisitos de patentabilidad y de esta manera es susceptible de ostentar el título de patente de invención.

8. Solicitudes concedidas en otros países para esta misma invención.

A manera informativa, pongo en conocimiento del Examinador que la patente EP 1 954 668 equivalente a la presente solicitud colombiana ha sido otorgada. Aún cuando entiendo que esta decisión de ninguna manera obligan al Despacho para decidir de igual forma, considero que por tratarse de una pregunta fáctica la determinación de la existencia de novedad, nivel inventivo y aplicación industrial, las decisiones de otras oficinas de patentes constituyen un antecedente persuasivo en la materia.

En virtud de lo anterior, solicito que se acepten las razones expuestas en el presente documento y en consecuencia, se otorgue el privilegio de patente de invención para el invento que se tramita en este expediente.

Atentamente,



ALVARO CORREA ORDÓÑEZ


C.C.No.79.143.366 de Usaquén

T.P.20.281

- Anexos:
- Capítulo reivindicatorio modificado
 - Texto y reivindicaciones de la solicitud divisional en CD
 - Recibo de pago de solicitud divisional
 - Copia de la carátula y reivindicaciones de la patente EP 1 954668
 - Página del Artículo "Side Reactions in Organic Synthesis"

REIVINDICACIONES


1. Un compuesto de la formula Ia o Ib





o

o esteroisómeros o formas de sal farmacéuticamente aceptables de los mismos, donde:


A es:










Bes:









Ces:









R_1 es $-C(O)R_3$, donde R_3 :






2. Un compuesto de la formula Ia





Ia


o estereoisómeros o formas de sal farmacéuticamente aceptables de los mismos, donde:

A es:













B es:







C es:








R_1 es $-C(O)R_3$, donde R_3 :





3 Un compuesto seleccionado del grupo que consiste de:

No.	Nombre del compuesto
2	(R)-4-Fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
56	(R)-4-fluoro-N-(1-(3-fluoro-5-(trifluorometil)fenil)-1-(4-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
57	(S)-4-fluoro-N-(1-(3-fluoro-5-(trifluorometil)fenil)-1-(4-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
59	(S)-N-(1-(3,4-difluorofenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
60	(R)-N-(1-(3,4-difluorofenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
61	(R)-4-fluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-metillbenzamida
62	(R)-3,4-difluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)benzamida
63	(R)-3-fluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)benzamida
64	(R)-3,5-difluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)benzamida
65	(R)-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
66	(R)-4-fluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
68	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
69	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
70	(R)-N-(1-(3-fluoro-5-(trifluorometil)fenil)-1-(4-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
71	(S)-N-(1-(3-cloro-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
72	(S)-N-(1-(2,4-difluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
73	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(3-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
74	(S)-N-(1-(3-cloro-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
264	(R)-4-fluoro-N-(1-(4-fluoro-3-hidroxifenil)-1-(3-fluoro-5-(1,1,2,2)-tetrafluoro etoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
267	N-(1-(3-ciano-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
268	(R)-tert-butil 2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)bencilcarbamato
269	Clorhidrato de (R)-N-(1-(3-(aminometil)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida

No.	Nombre del compuesto
270	(R)-N-(1-(3-(acetamidometil)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
271	(R)-4-fluoro-N-(1-(4-fluoro-3-(metilsulfonamidometil)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
272	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenil metilcarbamato
273	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
274	(R)-N-(1-(3-(1-amino-2-metil-1-oxopropan-2-iloxi)-4-fluorofenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
275	(R)-N-(1-(3-(2-cianopropan-2-iloxi)-4-fluorofenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
305	(R)-N-(1-(3-ciclopropoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
306	(R)-N-(1-(3-tert-butoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
309	(R)-N-(1-(3-ciclopropil-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
310	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutilfenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
316	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,2,2-trifluoroviniloxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
338	(R)-N-(1-(3-ciclopentil-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
339	(R)-metil 2-(2-fluoro-5-(1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenoxi)-2-metilpropanoato
340	(R)-N-(1-(3-(bencillamino)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
341	(R,E)-metil 3-(2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)fenil)acrilato
345	(R)-4-fluoro-N-(1-(4-fluoro-3-(5-metil-1,3,4-oxadiazol-2-il)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
348	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-(hidroximetil)fenil)etil)-3-(trifluorometil)benzamida
349 ^a	(R)-N-(1-(3-ciclopropoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
572	4-fluoro-N-(1-(4-fluoro-3-metilfenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
579	(R)-4-fluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
580	4-fluoro-N-(1-(3-fluoro-4-metoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
586	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)-3-(trifluorometil)benzamida
587	(R)-metil 5-(2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)fenoxi)pentanoato
588	(R)-4-fluoro-N-(1-(4-fluoro-3-(2-hidroxietoxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida

No.	Nombre del compuesto
589	Acido (R)-5-(2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)fenoxi)pentanóico
590	(R)-etil 2,2-difluoro-2-(2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)fenoxi)acetato
592	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)-4-metoxi-3-(trifluorometil)benzamida
593	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)-3-metoxibenzamida
607	(S)-N-(1-(3-bromo-4-fluorofenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
610	(R)-N-(1-(3-etoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
617	(S)-N-(1-(3-bromo-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
621	(R)-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
622	(R)-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
624	(R)-N-(1-(3-(ciclopentiloxi)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
626	(R)-N-(1-(3-(ciclohexilmetoxi)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
627	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
628	Propionato de (R)-2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)fenilo
629	(R)-4-fluoro-N-(1-(4-fluoro-3-(2,2,2-trifluoroetoxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
630	(R)-N-(1-(3-(ciclopropilmetoxi)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
631	(R)-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
632	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenil dimetilcarbamato
633	(R)-4-fluoro-N-(1-(3-fluoro-4-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
636	(R)-4-fluoro-N-(1-(4-fluoro-3-(3-hidroxi-2,2-dimetilpropoxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
637	(R)-4-fluoro-N-(1-(4-fluoro-3-propoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
638	(R)-N-(1-(3-(cianometoxi)-4-fluorofenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
639	(R)-etil 2-(2-fluoro-5-(1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenoxi)-2-metilpropanoato
640	Isopropilcarbamato de (R)-2-fluoro-5-(1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenilo
641	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenil etilcarbamato

No.	Nombre del compuesto
642	N-((1R)-1-(3-(1-cianoetoxi)-4-fluorofenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
643	(R)-3-ciano-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)benzamida
644	(R)-N-(1-(3-etoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
645	Acido (R)-2-(2-fluoro-5-(1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenoxi)-2-metilpropanóico
646	metil 2-(2-fluoro-5-((R)-1-(3-fluoro-5-(trifluorometil)fenil)-2-fenil-1-(3-(trifluorometil)benzamido)etil)fenoxi)propanoato
647	(R)-4,4,4-trifluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)butanamida
648	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutilfenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
649	(R)-2-ciano-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-feniletil)benzamida
652	(R)-N-(1-(4-fluoro-3-(1-hidroxi-2-metilpropan-2-iloxi)fenil)-1-(3-fluoro-5-(trifluorometil)fenil)-2-feniletil)-3-(trifluorometil)benzamida
653	(S)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
654	(S)-4-fluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
655	(S)-4-fluoro-N-(1-(4-fluoro-3-hidroxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
656	(R)-3-fluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida
657	(R)-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometoxi)benzamida
658	(R)-3,4-difluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida
659	(R)-3-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida
660	(R)-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometoxi)benzamida
661	(R)-3,4-difluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
662	(R)-3-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-5-(trifluorometil)benzamida
663	N-(1-(3-ciano-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
676	(R)-metil 2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)encilcarbamato
677	(R)-N-(1-(3-ciclobutoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
678	N-((1R)-1-(3-((2,2-difluorociclopropil)metoxi)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
680	2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzoato de metilo

No.	Nombre del compuesto
681	(R)-4-fluoro-N-(1-(4-fluoro-3-neopentilfenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
684	(R)-N-(1-(3-((dimetilamino)metil)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
690	2-fluoro-5-(1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzoate de metilo
694	(R)-2,4-difluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida
695	(R)-4-fluoro-N-(1-(4-fluoro-3-metoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida
696	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida
697	(R)-2,4-difluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida
700	(S)-4-fluoro-N-(1-(4-fluoro-3-(trifluorometoxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
701	(R)-4-fluoro-N-(1-(4-fluoro-3-(trifluorometoxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
708	Acido 2-(2-fluoro-5-((R)-1-(4-fluoro-3-(trifluorometil)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)fenoxi)propanóico
709	4-fluoro-N-((1R)-1-(4-fluoro-3-(1-hidroxipropan-2-iloxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
710	(R)-4-fluoro-N-(1-(4-fluoro-3-(viniloxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
711	(R)-4-fluoro-N-(1-(4-fluoro-3-(prop-1-en-2-iloxi)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
714	(R)-4-fluoro-N-(1-(4-fluoro-3-((isopropilamino)metil)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
715	(R)-N-(1-(3-((ciclopropilamino)metil)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
716	(R)-N-(1-(3-((butilamino)metil)-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
717	(R)-4-fluoro-N-(1-(4-fluoro-3-((isobutilamino)metil)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
718	(R)-4-fluoro-N-(1-(4-fluoro-3-(morfolinometil)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
720	(R)-4-fluoro-N-(1-(4-fluoro-3-((2-metoxietilamino)metil)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
726	(R)-4-fluoro-N-(1-(4-fluoro-3-(pirrolidin-1-ilmetil)fenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
728	(R)-N-(1-(3-ciclobutil-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
729	(R)-4-fluoro-N-(1-(4-fluoro-3-isopentilfenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida
730	(R)-N-(1-(3-ciclohexil-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida
731	(R)-3-ciano-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)benzamida

No.	Nombre del compuesto
958	(S)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-(4-metoxifenil)etil)-3-(trifluorometil)benzamida
959	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-(4-metoxifenil)etil)-3-(trifluorometil)benzamida
960	(S)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-(4-hidroxifenil)etil)-3-(trifluorometil)benzamida
961	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-1-(4-fluorofenil)-2-(4-hidroxifenil)etil)-3-(trifluorometil)benzamida
962	4-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)butanoato de (R) -metilo
963	Acido (R)-4-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)butanóico
964	Acido (S)-4-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)butanóico
965	5-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)pentanoato de (R) de metilo
966	Acido (R)-5-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)pentanóico
977	(R)-etil 6-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)hexanoato
978	Acido (R)-6-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)hexanóico
983	Acido (1r,4r)-4-((4-((R)-2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)metil)ciclohexano carboxílico
985	Acido (R)-7-(4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-fluorofenil)etil)fenoxi)heptanóico
1030	4-(2-(4-fluoro-3-(trifluorometil)benzamido)-2-(4-fluoro-3-isopropoxifenil)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)etil)benzoato de metilo
1031	4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-(hidroximetil)fenil)etil)-3-(trifluorometil)benzamida
1032	N-(2-(4-carbamoilfenil)-1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)etil)-4-fluoro-3-(trifluorometil)benzamida
1033	N-(2-(4-carbamoilfenil)-1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)etil)-4-fluoro-3-(trifluorometil)benzamida
1034	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-(hidroximetil)fenil)etil)-3-(trifluorometil)benzamida
1035	(R)-N-(2-(4-bromofenil)-1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)etil)-4-fluoro-3-(trifluorometil)benzamida
1036	(S)-N-(2-(4-bromofenil)-1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)etil)-4-fluoro-3-(trifluorometil)benzamida
1040	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-(2-hidroxiopropan-2-il)fenil)etil)-3-(trifluorometil)benzamida
1041	(S)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-hidroxifenil)etil)-3-(trifluorometil)benzamida y
1042	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-(4-hidroxifenil)etil)-3-(trifluorometil)benzamida

estereoisómeros o formas de sal farmacéuticamente aceptables de los mismos,

4. Un compuesto que es (R)-N-(1-(3-ciclopropoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4-fluoro-3-(trifluorometil)benzamida, estereoisómeros y formas de sal farmacéuticamente aceptables de los mismos.

5. Un compuesto de la reivindicación 3, donde el compuesto es (R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxifenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-3-(trifluorometil)benzamida, estereoisómeros y formas de sal farmacéuticamente aceptables de los mismos.

6. Un compuesto de la reivindicación 3, donde el compuesto es 2-amino-N-((R)-1-(3-ciclopropoxi-4-fluorofenil)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroetoxi)fenil)-2-feniletil)-4,4,4-trifluoro-3-hidroxi-3-(trifluorometil)butanamida, estereoisómeros y formas de sal farmacéuticamente aceptables de los mismos.

7. Una composición farmacéutica que comprende un compuesto de cualquiera de las reivindicaciones 1 a 6 y un portador farmacéuticamente aceptable.

8. La composición farmacéutica de conformidad con la reivindicación 7 caracterizada porque comprende además al menos un agente terapéutico adicional, donde el otro agente terapéutico adicional se selecciona de un inhibidor de reductasa HMG-CoA, un inhibidor de síntesis de colesterol, un inhibidor de absorción de colesterol, otro inhibidor de CETP, un inhibidor de secreción de MTP/Apo B, un modulador PPAR, un fibrato, niacina, una resina de intercambio iónico, un antioxidante, un inhibidor de ACAT, y un secuestrante de ácido biliar, un inhibidor de reabsorción de ácido biliar, un inhibidor de transportador de ácido biliar ileal, un inhibidor de ACC, un antihipertensivo, un modulador de receptor de estrógeno selectivo, un modulador de receptor de andrógeno selectivo, un antibiótico, un antidiabético y aspirina.

**DIRECCIÓN DE NUEVAS CREACIONES
CONVERSIÓN, DIVISIÓN Y FUSIÓN DE SOLICITUDES**

1. Identificación del Trámite

- ☐ Conversión ☒ División ☐ Fusión
- ☒ Patente de Invención
☐ Patente de Modelo de Utilidad
☐ Registro de Diseño Industrial
☐ Esquema de Trazado de Circuitos Integrados

2. Datos del solicitante

Persona Natural ☐

Persona Jurídica ☒

BRISTOL-MYERS SQUIBB COMPANY

Nombre o denominación / Nombre o razón social

Nombre del representante legal

Tipo de empresa

Micro ☐

Pequeña ☐

Mediana ☐

Otra ☒

Documento de identificación:

☐ C.C.

☐ C.E.

☐ NIT

☐ Otro

Número _____

Nacionalidad/País de constitución	Dirección del titular		Ciudad
Estados Unidos de América	Route 206 and Province Line Road, Princeton, NJ 08543-4000		Princeton
Dirección electrónica	No. Fax	Número telefónico	
alvaro.correa@bakermckenzie.com	3762211	6341500	

☐ Autorizo expresamente a la Superintendencia de Industria y Comercio para que todas las comunicaciones sean enviadas a través de la dirección de correo electrónico

3. Datos del apoderado:

Correa Ordoñez Alvaro

Apellidos y Nombre

79.143.366 de Usaquén

Documento de identificación

20.281

Tarjeta profesional

Dirección y domicilio		Ciudad
AV. 82 No. 10-62 Piso 6		Bogotá
Dirección electrónica	No. Fax	Número telefónico
alvaro.correa@bakermckenzie.co	3762211	6341500

En caso de haber presentado poder general para asuntos que se adelanten ante la Delegatura de Propiedad Industrial, sirvase indicar el número de su radicación o protocolo de poder general _____

4. Datos del trámite

CONVERSION

Expediente _____

De: _____

A: _____

DIVISION

Expediente 08.052.929

De: _____

A: _____

FUSION

Expediente _____

De: _____

A: _____

5. Comprobante de Pago No 12-0085735 Fecha 22 / 08 / 2012

6. Anexos

☒

Comprobante de pago de la tasa para la presentación de la corrección y/o modificación

☐

Poder, si fuere el caso con el que se acredita la representación

☐

Número de documento que ordena la comisión o fusión o división

☒

Documento que contiene la conversión, división o fusión de la solicitud

☒

Copia de la solicitud y sus anexos en formato magnético

7. Firma

Nombre y apellidos

Alvaro Correa Ordoñez

C.C. 79.143.366

Firma

Tarjeta Profesional 20.281

2012/013 34

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
NIT : 800.176.089-2
-/-

Industria y Comercio
SUPERINTENDENCIA

RECIBO DE CAJA

No. 12 - 0085735

Bogotá D.C., Agosto 22 de 2012 - 09:57:07

RECIBIDO DE : BAKER & MCKENZIE

NI 9007034.906

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	450027491	21/08/2012	73.321.000.00

*** Conceptos Pagados ***

CANT.	RENTISTICO	CONCEPTO	Vr.UNDITARIO	Vr.CONCEPTO
1	50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE INVENCIÓN	590.000.00	590.000.00
				\$590.000.00

SON: **QUINIENTOS NOVENTA MIL PESOS MONEDA CORRIENTE***

Responsable:

Recibo de Caja Aplicado al Expediente No. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 08-052929- -00006-0000

Fecha: 2012-09-21 16:19:21 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 523 RESPUESTA Folios: 91

Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C.- Colombia

Web: www.sic.gov.co e-mail: info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

Agosto 22 de 2012 - 09:57:33



(11) EP 1 954 668 B9

(12) CORRECTED EUROPEAN PATENT SPECIFICATION

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims DE 3
Claims EN 3
Claims FR 3

(48) Corrigendum issued on:
21.03.2012 Bulletin 2012/12

(45) Date of publication and mention
of the grant of the patent:
28.09.2011 Bulletin 2011/39

(21) Application number: 06839913.8

(22) Date of filing: 16.11.2006
- (51) Int Cl.:
C07C 211/29 (2006.01) C07C 215/08 (2006.01)
C07C 217/58 (2006.01) C07C 229/36 (2006.01)
C07C 229/38 (2006.01) C07C 233/09 (2006.01)
C07C 233/13 (2006.01) C07C 233/18 (2006.01)
C07C 233/56 (2006.01) C07C 233/60 (2006.01)
C07C 233/66 (2006.01) C07C 233/73 (2006.01)
C07C 233/78 (2006.01) C07C 235/20 (2006.01)
C07C 235/34 (2006.01)

(86) International application number:
PCT/US2006/060958

(87) International publication number:
WO 2007/062308 (31.05.2007 Gazette 2007/22)

(54) HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS
ALS CETP-HEMMER GEEIGNETE HOMO- UND HETEROCYCLISCHE VERBINDUNGEN
COMPOSÉS HOMO- ET HÉTÉROCYCLIQUES UTILES COMME INHIBITEURS DE CETP

(84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR Designated Extension States: HR MK RS (30) Priority: 23.11.2005 US 739374 P 13.11.2006 US 558979 (43) Date of publication of application: 13.08.2008 Bulletin 2008/33 (73) Proprietor: Bristol-Myers Squibb Company Princeton, NJ 08543-4000 (US) (72) Inventors: • SALVATI, Mark E. Pennington, New Jersey 08534 (US) • FINLAY, Heather Pennington, New Jersey 08534 (US) • CHEN, Bang-chi Princeton, New Jersey 08543 (US) • HARIKRISHNAN, Lalgudi S. Princeton, New Jersey 08543 (US) • JIANG, Ji Pennington, New Jersey 08534 (US)	• JOHNSON, James A. Pennington, New Jersey 08534 (US) • KAMAU, Muthoni G. Princeton, New Jersey 08543 (US) • LAWRENCE, Michael R. Pennington, New Jersey 08534 (US) • LI, Jianqing Wallingford, Connecticut 06492 (US) • LLOYD, John Pennington, New Jersey 08534 (US) • MILLER, Michael Matthew Pennington, New Jersey 08534 (US) • PI, Zulan Pennington, New Jersey 08534 (US) • QIAO, Jennifer X. Pennington, New Jersey 08534 (US) • RAMPULLA, Richard Pennington, New Jersey 08534 (US) • WANG, Tammy C. Pennington, New Jersey 08534 (US) • WANG, Yufeng Pennington, New Jersey 08534 (US) • YANG, Wu Pennington, New Jersey 08534 (US) • ROBERGE, Jacques Y. Pennington, New Jersey 08534 (US)
--	---

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


EP 1 954 668 B9

EP 1 954 668 B9

[0867] It is noted that the proceeding examples, while illustrative of the present invention, are not in sequential order and some example numbers may be missing.


Claims

1. A compound of formula Ia or Ib




or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein:

A is:




EP 1 954 668 B9


5



10




15



20

25



30

35

40


45

50

55

EP 1 954 668 B9


5
10
15
20
25
30
35
40
45
50
55




4

EP 1 954 668 B9


5
10
15
20
25
30
35
40
45
50
55




B is:



5




10




15

20




25




30

35




40




45

50




55

42



C is:



EP 1 954 668 B9

5

10

15

20

25

30


35

40










45

50

55




EP 1 954 668 B9




47

EP 1 954 668 B9


5




10




15




20



25




30




35


40



45




50



55


EP 1 954 668 B9



(b) -C(O)NHR₃, wherein the R₃ is:

EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55



EP 1 954 668 B9

5

10

15

20

25

30


35

40

45


50

55




EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55




EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55




EP 1 954 668 B9


5




10




15




20



30




35




40

(c) -C(O)NR₂R₃, wherein the NR₂R₃ is:

45






50




55


EP 1 954 668 B9






(e) $-\text{SO}_2\text{R}_5$ wherein the R_5 is:



(f) $-\text{CSNHR}_7$ wherein the R_7 is:




(g) $-\text{CH}_2\text{R}_8$ wherein the R_8 is:



57


EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55




EP 1 954 668 B9


5




10




15




20




25




30



35




40





45

50




55


EP 1 954 668 B9




(h) $-C(S)R_3$ wherein the R_3 is:



(i) $-C(=NR_3)Oalkyl$ wherein the R_3 is:




2. A compound of formula Ia



Ia


or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein:

A is:




EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55










EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55




EP 1 954 668 B9




EP 1 954 668 B9


5




10



15




20




25

30




35




40

45

50




55




10 R_1 is H or:

(a) $-C(O)R_3$, wherein R_3 :




EP 1 954 668 B9


5




10




15




20



25




30




35

40










45

50




55


EP 1 954 668 B9



EP 1 954 668 B9




(b) -C(O)NHR₃, wherein the R₃ is:




EP 1 954 668 B9


5




10




15




20




25




30




35



40



45




50


55

EP 1 954 668 B9


5




10



15




20




25


30




35



40




45



50

55



10



20



30

35




45

50


55

592


EP 1 954 668 B9



(f) -CSNHR₇ wherein the R₇ is:




(g) -CH₂R₈ wherein the R₈ is:




EP 1 954 668 B9

5
10
15
20
25
30
35
40
45
50
55




EP 1 954 668 B9


5




10



15




20




25


30



35




40




45










50



55



EP 1 954 668 B9



EP 1 954 668 B9

3. A compound of claim 1, wherein the compound is selected from the group consisting of:

5

10

15

20

25

30

35

40

45

50

55

No.	Compound Name
2	(R)-4-Fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
56	(R)-4-fluoro-N-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
57	(S)-4-fluoro-N-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
59	(S)-N-(1-(3,4-difluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
60	(R)-N-(1-(3,4-difluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
61	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-methylbenzamide
62	(R)-3,4-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)benzamide
63	(R)-3-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)benzamide
64	(R)-3,5-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)benzamide
65	(R)-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
66	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
68	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
69	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
70	(R)-N-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
71	(S)-N-(1-(3-chloro-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
72	(S)-N-(1-(2,4-difluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
73	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(3-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
74	(S)-N-(1-(3-chloro-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide #
264	(R)-4-fluoro-N-(1-(4-fluoro-3-hydroxyphenyl)-1-(3-fluoro-5-(1,1,2,2)-tetrafluoro ethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
267	N-(1-(3-cyano-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
268	(R)-tert-butyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzylcarbamate
269	(R)-N-(1-(3-(aminomethyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide hydrochloride
270	(R)-N-(1-(3-(acetamidomethyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
271	(R)-4-fluoro-N-(1-(4-fluoro-3-(methylsulfonamidomethyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
272	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl methylcarbamate

598

EP 1 954 668 B9

No. Compound Name	
273	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5(1,1,2,2-tetrafluoro ethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
274	(R)-N-(1-(3-(1-amino-2-methyl-1-oxopropan-2-yloxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
275	(R)-N-(1-(3-(2-cyanopropan-2-yloxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
305	(R)-N-(1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
306	(R)-N-(1-(3-tert-butoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
309	(R)-N-(1-(3-cyclopropyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
310	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutylphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
316	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,2,2-trifluorovinylloxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
337	2-amino-N-(R)-1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5(1,1,2,2-tetrafluoroethoxy)phenyl-2-phenylethyl)-4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl) butanamide
338	(R)-N-(1-(3-cyclopentyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
339	(R)-methyl 2-(2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)-2-methylpropanoate
340	(R)-N-(1-(3-(benzylamino)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
341	(R,E)-methyl 3-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenyl)acrylate
344	((R)-4-fluoro-N-(1-(4-fluoro-3-(hydrazinecarbonyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
345	(R)-4-fluoro-N-(1-(4-fluoro-3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
348	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(hydroxymethyl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
349A	(R)-N-(1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
572	4-fluoro-N-(1-(4-fluoro-3-methylphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
579	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
580	4-fluoro-N-(1-(3-fluoro-4-methoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
586	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
587	(R)-methyl 5-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)pentanoate
588	(R)-4-fluoro-N-(1-(4-fluoro-3-(2-hydroxyethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
589	(R)-5-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)pentanoic acid

55	
50	
45	
40	
35	
30	
25	
20	
15	
10	
5	
(continued)	
No.	Compound Name
590	(R)-ethyl 2,2-difluoro-2-(2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)acetate
592	(R)-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-4-methoxy-3-(trifluoromethyl)benzamide
593	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-3-methoxybenzamide
607	(S)-N-(1-(3-bromo-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
610	(R)-N-(1-(3-ethoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
617	(S)-N-(1-(3-bromo-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
621	(R)-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
622	(R)-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
624	(R)-N-(1-(3-(cyclopentylloxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
626	(R)-N-(1-(3-(cyclohexylmethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
627	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
628	(R)-2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenyl propionate
629	(R)-4-fluoro-N-(1-(4-fluoro-3-(2,2,2-trifluoroethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
630	(R)-N-(1-(3-(cyclopropylmethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
631	(R)-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
632	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl dimethylcarbamate
633	(R)-4-fluoro-N-(1-(3-fluoro-4-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
636	(R)-4-fluoro-N-(1-(4-fluoro-3-(3-hydroxy-2,2-dimethylpropoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
637	(R)-4-fluoro-N-(1-(4-fluoro-3-propoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
638	(R)-N-(1-(3-(cyanomethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
639	(R)-ethyl 2-(2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)-2-methylpropanoate
640	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl isopropylcarbamate
641	(R)-2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenyl ethylcarbamate
642	N-((1R)-1-(3-(1-cyanoethoxy)-4-fluorophenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
643	(R)-3-cyano-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)benzamide

(continued)	
No.	Compound Name
644	(R)-N-(1-(3-ethoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
645	(R)-2-(2-fluoro-5-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)-2-methylpropanoic acid
646	methyl 2-(2-fluoro-5-((R)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenyl-1-(3-(trifluoromethyl)benzamido)ethyl)phenoxy)propanoate
647	(R)-4,4,4-trifluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)butanamide
648	(R)-4-fluoro-N-(1-(4-fluoro-3-isobutylphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
649	(R)-2-cyano-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-phenylethyl)benzamide
652	(R)-N-(1-(4-fluoro-3-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
653	(S)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
654	(S)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
655	(S)-4-fluoro-N-(1-(4-fluoro-3-hydroxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
656	(R)-3-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
657	(R)-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethoxy)benzamide
658	(R)-3,4-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
659	(R)-3-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
660	(R)-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethoxy)benzamide
661	(R)-3,4-difluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
662	(R)-3-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5-(trifluoromethyl)benzamide
663	N-(1-(3-cyano-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
676	(R)-methyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzylcarbamate
677	(R)-N-(1-(3-cyclobutoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
678	N-((1R)-1-(3-((2,2-difluorocyclopropyl)methoxy)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
680	methyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzoate
681	(R)-4-fluoro-N-(1-(4-fluoro-3-neopentylphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide

No. Compound Name	
684	(R)-N-(1-(3-((dimethylamino)methyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
687	2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-N-methylbenzamide
688	2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-N,N-dimethylbenzamide
690	methyl 2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzoate
694	(R)-2,4-difluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
695	(R)-4-fluoro-N-(1-(4-fluoro-3-methoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
696	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
697	(R)-2,4-difluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
700	(S)-4-fluoro-N-(1-(4-fluoro-3-(trifluoromethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
701	(R)-4-fluoro-N-(1-(4-fluoro-3-(trifluoromethoxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
708	2-(2-fluoro-5-((R)-1-(4-fluoro-3-(trifluoromethyl)benzamido)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)phenoxy)propanoic acid
709	4-fluoro-N-((1R)-1-(4-fluoro-3-(1-hydroxypropan-2-yloxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
710	(R)-4-fluoro-N-(1-(4-fluoro-3-(vinylloxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
711	(R)-4-fluoro-N-(1-(4-fluoro-3-(prop-1-en-2-yloxy)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
714	(R)-4-fluoro-N-(1-(4-fluoro-3-((isopropylamino)methyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
715	(R)-N-(1-(3-((cyclopropylamino)methyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
716	(R)-N-(1-(3-((butylamino)methyl)-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
717	(R)-4-fluoro-N-(1-(4-fluoro-3-((isobutylamino)methyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
718	(R)-4-fluoro-N-(1-(4-fluoro-3-(morpholinomethyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
719	N-(1-(3-(carbamoyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
720	(R)-4-fluoro-N-(1-(4-fluoro-3-((2-methoxyethylamino)methyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
726	(R)-4-fluoro-N-(1-(4-fluoro-3-(pyrrolidin-1-ylmethyl)phenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
728	(R)-N-(1-(3-(cyclobutyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide
729	(R)-4-fluoro-N-(1-(4-fluoro-3-isopentylphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide
730	(R)-N-(1-(3-(cyclohexyl-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide

No. Compound Name	
731	(R)-3-cyano-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)benzamide
958	(S)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-methoxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
959	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-methoxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
960	(S)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
961	(R)-4-fluoro-N-(1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide
962	(R)-methyl 4-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)butanoate
963	(R)-4-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)butanoic acid
964	(S)-4-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)butanoic acid
965	(R)-methyl 5-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)pentanoate
966	(R)-5-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)pentanoic acid
977	(R)-ethyl 6-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)hexanoate
978	(R)-6-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)hexanoic acid
983	(1r,4r)-4-(((4-(R)-2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)methyl)cyclohexanecarboxylic acid
985	(R)-7-(4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-fluorophenyl)ethyl)phenoxy)heptanoic acid
1030	methyl 4-(2-(4-fluoro-3-(trifluoromethyl)benzamido)-2-(4-fluoro-3-isopropoxyphenyl)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)benzoate
1031	4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(hydroxymethyl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
1032	(R)-2-(4-(4-carbamoylphenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1033	(S)-2-(4-(4-carbamoylphenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1034	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(hydroxymethyl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
1035	(R)-N-(2-(4-bromophenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1036	(S)-N-(2-(4-bromophenyl)-1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)ethyl)-4-fluoro-3-(trifluoromethyl)benzamide
1040	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)ethyl)-3-(trifluoromethyl)benzamide
1041	(S)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide and
1042	(R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-(4-hydroxyphenyl)ethyl)-3-(trifluoromethyl)benzamide,

86


EP 1 954 668 B9

stereoisomers or pharmaceutically acceptable salt forms thereof.

4. A compound of claim 3 that is (R)-N-(1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)-benzamide, stereoisomers and pharmaceutically acceptable salt forms thereof.
5. A compound of claim 3, wherein the compound is (R)-4-fluoro-N-(1-(4-fluoro-3-isopropoxyphenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(trifluoromethyl)benzamide, stereoisomers and pharmaceutically acceptable salt forms thereof.
6. A compound of claim 3, wherein the compound is 2-amino-N-((R)-1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanamide, stereoisomers and pharmaceutically acceptable salt forms thereof.
7. A pharmaceutical composition comprising a compound of any one of claims 1 to 6.
8. The pharmaceutical composition of claim 6 further comprising a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 7 further comprising at least one additional therapeutic agent.
10. A compound of any one of claims 1 to 6 for use in a method of inhibiting the cholesteryl ester transfer protein.
11. A compound of any one of claims 1 to 6 for use in a method for treating, preventing or slowing the progression of Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal.
12. A compound of any one of claims 1 to 6 for use in a method for treating, preventing or slowing the progression of a disease requiring cholesteryl ester transfer protein inhibitor therapy.
13. A compound of any one of claims 1 to 6 for use in a method for inhibiting remnant lipoprotein production.
14. A compound of any one of claims 1 to 6 for use in a method of raising HDL cholesterol in a mammal.

Patentansprüche

1. Verbindung der Formel Ia oder Ib



oder Stereoisomere oder pharmazeutisch verträgliche Salzformen davon, worin:

A:




3 0402 00291 8607

F. Zaragoza Dörwald

WILEY-VCH

Side Reactions in Organic Synthesis

A Guide to Successful Synthesis Design



Florencio Zaragoza Dönwald

Side Reactions in Organic Synthesis

A Guide to Successful Synthesis Design



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

12-27-07P03:22 RCVD

Preface

Most non-chemists would probably be horrified if they were to learn how many attempted syntheses fail, and how inefficient research chemists are. The ratio of successful to unsuccessful chemical experiments in a normal research laboratory is far below unity, and synthetic research chemists, in the same way as most scientists, spend most of their time working out what went wrong, and why.

Despite the many pitfalls lurking in organic synthesis, most organic chemistry textbooks and research articles do give the impression that organic reactions just proceed smoothly and that the total synthesis of complex natural products, for instance, is maybe a labor-intensive but otherwise undemanding task. In fact, most syntheses of structurally complex natural products are the result of several years of hard work by a team of chemists, with almost every step requiring careful optimization. The final synthesis usually looks quite different from that originally planned, because of unexpected difficulties encountered in the initially chosen synthetic sequence. Only the seasoned practitioner who has experienced for himself the many failures and frustrations which the development (sometimes even the repetition) of a synthesis usually implies will be able to appraise such work.

This book attempts to highlight the competing processes and limitations of some of the most common and important reactions used in organic synthesis. Awareness of these limitations and problem areas is important for the design of syntheses, and might also aid elucidation of the structure of unexpected products. Two chapters of this book cover the structure-reactivity relationship of organic compounds, and should also aid the design of better syntheses.

Chemists tend not to publish negative results, because these are, as opposed to positive results, never definite (and far too copious). Nevertheless, I have ventured to describe some reactions as difficult or impossible. A talented chemist might, however, succeed in performing such reactions anyway, for what I congratulate him in advance. The aim of this book is not to stop the reader from doing bold experiments, but to help him recognize his experiment as bold, to draw his attention to potential problems, and to inspire, challenge, and motivate.

Author

Dr. Florencio Zaragoza Dörwald
Medicinal Chemistry
Novo Nordisk A/S
Novo Nordisk Park
2760 Måløv
Denmark

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.:
applied for

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library.

Bibliographic information published by
Die Deutsche Bibliothek
Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at
<<http://dnb.ddb.de>>.

© 2005 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany.

Printed on acid-free paper.

Typesetting Kühn & Weyh, Satz und Medien,
Freiburg
Printing Strauss GmbH, Mörlenbach
Bookbinding Litges & Dopf Buchbinderei GmbH,
Heppenheim

ISBN 3-527-31021-5

